Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

All products: not a benefit

Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 · 2mg & 0.035mg · tablets, 21-pack

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cyproterone/Ethinyl Estradiol · DIN 02309556 Manufacturer: Teva Canada Limited; listing date 2008-12-03 Health Canada: Marketed since 2018-03-08 · brand TEVA-CYPROTERONE / ETHINYL ESTRADIOL · ATC G03HB01 CYPROTERONE AND ESTROGEN · form Tablet · route Oral · ingredients CYPROTERONE ACETATE 2 MG, ETHINYL ESTRADIOL 0.035 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79517 · Verify on the e-Formulary ↗ (DIN 02309556)

Source record
DIN 02309556: Teva-Cyproterone/Ethinyl Estradiol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 683200100; group id 792; item number 1929; lccId None; manufacturer id TEV Source form: Tab-21 Pk; strength: 2mg & 0.035mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $23.3400; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79517
Interchangeable products
AMB-Cyproterone Acetate/EthinylEstradiol · DIN 02564424 · not recorded Cleo-35 · DIN 02436736 · not recorded Cyestra-35 · DIN 02290308 · not recorded Diane-35 · DIN 02233542 · not recorded Ran-Cyproterone/Ethinyl Estradiol · DIN 02425017 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DIANE-35 (cyproterone acetate and ethinyl estradiol) is indicated for:  treatment of women with severe acne, with associated symptoms of androgenization, including seborrhea and mild hirsutism. DIANE-35 should be used only when acne is unresponsive to topical therapy and oral antibiotic treatments. Note: DIANE-35 should not be prescribed for the purpose of contraception alone. However, when taken as recommended (see DOSAGE AND ADMINISTRATION), DIANE-35 will provide reliable contraception in patients treated for the above clinical conditions. If patient compliance is uncertain and contraception is necessary, then a supplementary non-hormonal contraceptive method should be considered. Geriatrics DIANE-35 is not indicated after menopause. Pediatrics DIANE-35 is only indicated after menarche. https://pdf.hres.ca/dpd_pm/00038573.PDF PM date: March 16, 2017 Source product: DIANE-35; DIN 02233542; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Teva-Cyproterone/Ethinyl Estradiol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026